1. Scrip

BIOSECURE Act Diluted Significantly, But China Plus Strategy Still Accelerating: Strides MD

Significant growth expected in H2 FY25

 
• By Vibha Ravi

A time extension to US companies to shift business away from a few Chinese firms under the proposed BIOSECURE Act has disappointed the Strides MD. However, the China plus strategy continues to drive business and capacity expansion for auto-injectors required by GLP-1 customers is expected

Simmering US-China Tensions Are Leading To Business Rebalancing
Simmering US-China Relations Necessitate Business Rebalancing • Source: Shutterstiock

US lawmakers had business realities and industry requests in mind when they amended the BIOSECURE Bill allowing US companies time till 2032 to shift business away from select Chinese ones, but that has disappointed Indian contract development and manufacturing (CDMO) firms.

“The BIOSECURE Act has been diluted quite significantly and there is now a seven-to-eight-year window for the companies dependent on China to find alternative solutions,” Strides Pharma Science Limited...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip